Bristol-Myers Squibb (BMY) -5.2% premarket after it suspends its study of a drug intended to...

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

Bristol-Myers Squibb (BMY) -5.2% premarket after it suspends its study of a drug intended to treat liver disease hepatitis C after a patient suffered heart failure, raising questions about the drug's potential and the $2.5B it paid earlier this year to buy the company that developed it. Companies that could benefit from BMY's woes: GILD +8.8%, IDIX +8.2% premarket.